Mr. Francois Roberge reports

LSL PHARMA GROUP GRANTS STOCK OPTIONS

LSL Pharma Group Inc. has granted an aggregate of 960,000 stock options to its non-executive directors and to certain executives and employees as part of their compensation. The options have an exercise price of 52 cents per share and are exercisable for a period of 10 years from the date of grant. Options granted to non-executive directors vest immediately as of the date of grant while options to executives and employees vest over three years. The options were granted in accordance with the corporation's stock option plan.

All of the options (and any common shares issuable upon exercise or settlement thereof) will be subject to a four-month hold period pursuant to the policies of the TSX Venture Exchange and applicable securities law.

About LSL Pharma Group Inc.

LSL Pharma Group is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and commercialization of high-quality sterile ophthalmic pharmaceutical products as well as pharmaceutical, cosmetic and natural health products in solid, semi-solid and liquid dosage forms. Leveraging its technical expertise, certified facilities and experienced team, LSL Pharma delivers high-quality solutions that meet the highest industry standards. The wholly owned subsidiaries of LSL Pharma include Steri-Med Pharma Inc., LSL Laboratory Inc., Virage Sante Inc., Dermolab Pharma Ltd., Du-Var Laboratory Inc. and Juno OTC Inc.

We seek Safe Harbor.